Merck, Inc.
🇵🇭Philippines
Extended Release (ER) Niacin/Laropiprant Add on Study (0524A-082)
Phase 3
Withdrawn
- Conditions
- Dyslipidemia
- Interventions
- Drug: placebo (unspecified)Drug: niacin (+) laropiprant
- First Posted Date
- 2008-04-22
- Last Posted Date
- 2015-04-09
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Registration Number
- NCT00664287
Telcagepant (MK-0974) Treatment of Migraine in Participants With Stable Vascular Disease (MK-0974-034)
Phase 3
Completed
- Conditions
- Migraine DisordersCerebrovascular AccidentPeripheral Vascular DiseasesHeart DiseaseTIA (Transient Ischemic Attack)Vascular Diseases
- Interventions
- Drug: TelcagepantDrug: Acetaminophen/ParacetamolDrug: Placebo to TelcagepantDrug: Placebo to Acetaminophen/Paracetamol
- First Posted Date
- 2008-04-21
- Last Posted Date
- 2018-10-19
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 165
- Registration Number
- NCT00662818
Safety and Efficacy Pilot Study of AzaSite® for Four Weeks in Subjects With Blepharitis
- First Posted Date
- 2008-04-11
- Last Posted Date
- 2011-09-26
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 20
- Registration Number
- NCT00656539
- Locations
- 🇺🇸
Ophthalmic Consultants of Long Island, Lynbrook, New York, United States
Dialysis of Sugammadex in Participants With Severe Renal Impairment (Study 19.4.333) (P05773)
- First Posted Date
- 2008-04-11
- Last Posted Date
- 2015-03-10
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 6
- Registration Number
- NCT00656799
A Study Evaluating Dalotuzumab (MK-0646) in Combination With Erlotinib for Participants With Non-Small Cell Lung Cancer (MK-0646-007)
Phase 2
Completed
- Conditions
- Carcinoma, Non-small-cell Lung
- Interventions
- First Posted Date
- 2008-04-08
- Last Posted Date
- 2018-08-08
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 95
- Registration Number
- NCT00654420
Journey for Control of Diabetes Study (0431-111)
Not Applicable
Completed
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Behavioral: Individual Education (IE)Behavioral: Interactive Dialogue to Educate and Activate (IDEA)
- First Posted Date
- 2008-04-03
- Last Posted Date
- 2017-04-28
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 621
- Registration Number
- NCT00652509
A Dose Escalation Study of Adavosertib (MK-1775) in Combination With Either Gemcitabine, Cisplatin, or Carboplatin in Adults With Advanced Solid Tumors (MK-1775-001)
Phase 1
Completed
- Conditions
- Solid Tumors
- Interventions
- First Posted Date
- 2008-04-01
- Last Posted Date
- 2023-09-21
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 206
- Registration Number
- NCT00648648
A Study to Evaluate the Safety, Tolerability and Plasma Concentration Profiles of MK0633 in Asthmatic Children Aged 12 to Less Than 16 Years (0633-019)
Phase 1
Completed
- Conditions
- Asthma
- First Posted Date
- 2008-03-31
- Last Posted Date
- 2015-06-01
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 12
- Registration Number
- NCT00646789
A Study to Test V930/V932 in Patients With Cancers Expressing Human Epidermal Growth Factor Receptor 2 (HER-2) and/or Carcinoembryonic Antigen (CEA)(V930-003)(COMPLETED)
Phase 1
Completed
- Conditions
- Cancer
- Interventions
- Biological: V930Biological: V932
- First Posted Date
- 2008-03-31
- Last Posted Date
- 2015-03-13
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 41
- Registration Number
- NCT00647114
Vorinostat (MK-0683, SAHA [Suberoylanilide Hydroxamic Acid]) + Lenalidomide + Dexamethasone in Multiple Myeloma (MM) (MK-0683-074)
Phase 1
Completed
- Conditions
- Relapsed or Refractory Multiple Myeloma
- Interventions
- First Posted Date
- 2008-03-25
- Last Posted Date
- 2020-11-18
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 31
- Registration Number
- NCT00642954
© Copyright 2025. All Rights Reserved by MedPath